Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines

被引:28
|
作者
Perez, EA [1 ]
Buckwalter, CA [1 ]
机构
[1] Mayo Clin Jacksonville, Div Hematol Oncol, Jacksonville, FL 32224 USA
关键词
cell culture; breast; lung; etoposide; paclitaxel;
D O I
10.1007/s002800050765
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effect of schedule on the interaction of etoposide with paclitaxel in vitro against the A549 human lung cancer cell line and the MDA-231 and MCF-7 human breast cancer cell lines. Methods: Exposure schedules that were 24-h concurrent, 24-h sequential, and sequential 24-h with a 24-h intervening drug-free period were quantitatively evaluated by the use of the median-effect principle and the combination index. The clonogenic assay was used to assess cytotoxicity, and calculations were done with computer software. Results: Concurrent exposures were less than additive in two of the three cell lines tested. Sequential 24-hour and sequential 24-h with an intervening 24-h drug-free period showed synergism at high effect levels in all three cell lines. Similar synergistic interactions were found when either agent was administered first. Conclusions: These results show a schedule-dependent cytotoxic interaction between etoposide and paclitaxel in the human lung and breast cancer cell lines evaluated, with optimal synergism occurring with sequential, but not with concurrent, treatment.
引用
收藏
页码:448 / 452
页数:5
相关论文
共 50 条
  • [31] Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45
    Toiyama, Y
    Tanaka, K
    Konishi, N
    Mohri, Y
    Tonouchi, H
    Miki, C
    Kusunoki, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (03) : 368 - 375
  • [32] Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45
    Yuji Toiyama
    Koji Tanaka
    Naomi Konishi
    Yasuhiko Mohri
    Hitoshi Tonouchi
    Chikao Miki
    Masato Kusunoki
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 368 - 375
  • [33] SEQUENCE-DEPENDENT SYNERGISTIC CYTOTOXICITY OF FLUORODEOXYURIDINE (FDURD) AND ETOPOSIDE (VP-16) IN L1210 CELLS
    CHRISTENSEN, SR
    DAMON, LE
    WONG, DC
    CADMAN, EC
    CLINICAL RESEARCH, 1986, 34 (01): : A74 - A74
  • [34] Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeedanamycin - Discussion
    Ferguson, MK
    Nguyen
    Rusch, VW
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (05): : 915 - 915
  • [35] Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines
    He, Xuejun
    Zhang, Tingrong
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 68 (02) : 411 - 418
  • [36] Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines
    Xuejun He
    Tingrong Zhang
    Cell Biochemistry and Biophysics, 2014, 68 : 411 - 418
  • [37] Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner
    Kubota, T
    Egawa, T
    Furukawa, T
    Otani, Y
    Watanabe, M
    Furukawa, T
    Kumai, K
    ANTICANCER RESEARCH, 2001, 21 (4A) : 2597 - 2600
  • [38] Sequence-dependent cytotoxicity of second-generation oligonucleotides
    Drygin, D
    Barone, S
    Bennett, CF
    NUCLEIC ACIDS RESEARCH, 2004, 32 (22) : 6585 - 6594
  • [39] Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines
    Ohsaki, Y
    Ishida, S
    Fujikane, T
    Kikuchi, K
    ONCOLOGY, 1996, 53 (04) : 327 - 333
  • [40] Synergistic cancer cell cytotoxicity of TLK286 (TELCYTA™) in combination with carboplatin, cisplatin, doxorubicin, docetaxel, paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal cancer cell lines.
    Xu, H
    Namgoong, SY
    Roth, E
    Tran, V
    Schow, S
    Brown, GL
    Keck, JG
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6241S - 6242S